CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI) Diagnosis and Prognosis of Coronary Artery Disease with SPECT and PET Incidence, Determinants, and Outcomes of Left and Right Radial Access Use in Patients Undergoing Percutaneous Coronary Intervention in the United Kingdom-A National Perspective Using the BCIS Dataset Decreased inspired oxygen stimulates de novo formation of coronary collaterals in adult heart Acute Myocardial Infarction Prevalence of Angina Among Primary Care Patients With Coronary Artery Disease Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion: The DECISION-CTO Trial 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

Original ResearchVolume 75, Issue 8, March 2020

JOURNAL:J Am Coll Cardiol. Article Link

Long-Term Outcomes of Anticoagulation for Bioprosthetic Valve Thrombosis

I Petrescu, AC Egbe, F Ionescu et al. Keywords: anticoagulation; bioprosthetic valve thrombosis; prosthetic valve failure

ABSTRACT


BACKGROUND - Early in the prevention and treatment of bioprosthetic valve thrombosis (BPVT), anticoagulation is effective, but the long-term outcome after BPVT is unknown.

 

OBJECTIVES - The goal of this study was to assess the long-term outcomes of patients with BPVT treated with anticoagulation.

 

METHODS - This analysis was a matched cohort study of patients treated with warfarin for suspected BPVT at the Mayo Clinic between 1999 and 2017.

 

RESULTS - A total of 83 patients treated with warfarin for suspected BPVT (age 57 ± 18 years; 45 men [54%]) were matched to 166 control subjects; matching was performed according to age, sex, year of implantation, and prosthesis type and position. Echocardiography normalized in 62 patients (75%) within 3 months (interquartile range [IQR]: 1.5 to 6 months) of anticoagulation; 21 patients (25%) did not respond to warfarin. Median follow-up after diagnosis was 34 months (IQR: 17 to 54 months). There was no difference in the primary composite endpoint between the patients with BPVT and the matched control subjects (log-rank test, p = 0.79), but the former did have a significantly higher rate of major bleeding (12% vs. 2%; p < 0.0001). BPVT recurred (re-BPVT) in 14 (23%) responders after a median of 23 months (IQR: 11 to 39 months); all but one re-BPVT patient responded to anticoagulant therapy. Patients with BPVT had a higher probability of valve re-replacement (68% vs. 24% at 10 yearspost-BPVT; log-rank test, p < 0.001).

 

CONCLUSIONS - BPVT was associated with re-BPVT and early prosthetic degeneration in a significant number of patients. Indefinite warfarin anticoagulation should be considered after a confirmed BPVT episode, but this strategy must be balanced against an increased risk of bleeding.